Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 10;3(23):4043-4049.
doi: 10.1182/bloodadvances.2019000930.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Ibrahim Aldoss  1 , Sanjeet Dadwal  2 , Jianying Zhang  3 , Bernard Tegtmeier  2 , Matthew Mei  1 , Shukaib Arslan  1 , Monzr M Al Malki  1 , Amandeep Salhotra  1 , Haris Ali  1 , Ahmed Aribi  1 , Karamjeet Sandhu  1 , Samer Khaled  1 , David Snyder  1 , Ryotaro Nakamura  1 , Anthony S Stein  1 , Stephen J Forman  1 , Guido Marcucci  1 , Vinod Pullarkat  1
Affiliations
Free PMC article

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Ibrahim Aldoss et al. Blood Adv. .
Free PMC article

Abstract

The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment with VEN-HMAs results in prolonged cytopenia, thereby exposing patients to invasive fungal infections (IFIs). Here, we retrospectively studied a cohort of 119 AML patients treated with VEN-HMAs and analyzed the occurrence of IFIs, as well as our practice of antifungal prophylaxis, with the aim to identify the nature and risk factors for IFIs and their association with the type of antifungal prophylaxis used. The intended antifungal prophylaxis was micafungin in 38% of patients, azoles in 41% of patients, and none in 21% of patients. Older age was associated with no antifungal prophylaxis or micafungin use and lesser use of azoles (P = .043). We recorded 15 (12.6%) patients who developed probable or proven IFIs, with a median onset of 72 days (range, 35-281) after starting therapy. IFIs were more common among nonresponders compared with responders to VEN-HMA therapy (22% vs 6%, P = .0132) and in r/r compared with newly diagnosed AML (19% vs 5%, P = .0498); however, the antifungal prophylaxis used, patient age, hypomethylating agent schedule, history of prior allogeneic transplant, and initial neutropenia duration did not influence the development of IFIs during therapy. We conclude that the overall risk of IFIs during VEN-HMA therapy is low. The risk of IFIs is higher in nonresponders and in those who were treated in the r/r setting; these patients need reevaluation of their antifungal prophylaxis to minimize the risk of IFIs during therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: I.A. serves on advisory boards for AbbVie and Agios Pharmaceuticals, is a member of the speakers bureau for Jazz Pharmaceuticals, and is a consultant for Autolus Therapeutics. S.D. has acted as a consultant for and serves on advisory boards for Merck, Clinigen, and Janssen, is a member of the speakers bureau for Merck, and has received research support from Merck, Shire, and Chimerix. A.S. has served as a consultant for Kadmon Corporation and has received research funding from Celgene. R.N. serves on advisory boards for Merck and Celgene and has a research collaboration with Jazz Pharmaceuticals. A.S.S. is a member of the speakers bureau for Amgen, Celgene, and Stemline Therapeutics. G.M. is a member of the speakers bureau for AbbVie. V.P. has served on advisory boards for AbbVie and Jazz Pharmaceuticals and is member of the speakers bureau for Jazz Pharmaceuticals, Amgen, Novartis, and AbbVie. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DiNardo CD, Pratz K, Pullarkat V, et al. . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. - PMC - PubMed
    1. Lübbert M, Rüter BH, Claus R, et al. . A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3):393-401. - PMC - PubMed
    1. Kantarjian HM, Thomas XG, Dmoszynska A, et al. . Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677. - PMC - PubMed
    1. Aldoss I, Yang D, Aribi A, et al. . Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404-e407. - PMC - PubMed
    1. DiNardo CD, Rausch CR, Benton C, et al. . Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401-407. - PubMed

MeSH terms